Where an acute strain might respond within two to three weeks, chronic tendinopathies may need eight to twelve weeks of consistent micro-dosing before significant improvement becomes apparent
One should not use AOD-9604 if they: Are pregnant or breastfeeding Are a minor Have a current or recent history of cancer (particularly hormone-sensitive cancers) Have uncontrolled diabetes or significant insulin resistance Have active thyroid disease that is not well-managed Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds Comprehensive labs including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels should be run before starting any peptide therapy and monitored regularly throughout
What affects whether you notice anything at all: Whether you had a true nutrient deficiency to correct (especially for B12-related fatigue) Your calorie intake, protein, and consistency Sleep, stress, and movement Whether youre also using evidence-based tools (like FDA-indicated GLP-1 options when appropriate) Medical disclaimer This article is for education only and is not medical advice
Since these guidelines are preliminary, researchers should conduct initial dose-finding studies to identify the optimal range for their specific models
